Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women's Health Inc. (AWH) delivers innovative diagnostic solutions for gynecologic diseases through its AI-powered blood tests. This comprehensive news hub provides investors and healthcare professionals with essential updates on the company's advancements in ovarian cancer risk assessment and women's health diagnostics.
Access timely reports on regulatory milestones, clinical study results, and financial performance. Our curated collection includes press releases about OvaWatch developments, partnership announcements with medical institutions, and analyses of emerging trends in precision diagnostics.
Key content categories cover earnings reports, product innovation updates, strategic collaborations, and peer-reviewed research validations. Each update maintains clinical context while focusing on business implications for informed decision-making.
Bookmark this page for centralized access to Aspira's evolving diagnostic portfolio and market-moving announcements. Check regularly for objective reporting on developments impacting women's healthcare and diagnostic technology sectors.
Aspira Women's Health (NASDAQ:AWH), a bio-analytical based women's health company specializing in gynecologic disease diagnostic tools, has announced a trading symbol change. Starting April 17, 2025, the company's Common Stock will transition from trading under 'AWH' to trading under the new symbol 'AWHL' on the OTC Markets Group platforms.
Aspira Women's Health (NASDAQ:AWH) has received a delisting notification from Nasdaq on April 15, 2025. The company's shares will be suspended from trading on Nasdaq effective April 17, 2025, due to non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining a minimum stockholders' equity of $2.5 million for continued listing on the Nasdaq Capital Market.
Following the suspension, AWH's common stock is expected to transition to trading on OTC markets under the same symbol 'AWH'. The company, which focuses on developing gynecologic disease diagnostic tools, will no longer maintain its Nasdaq listing status.
Aspira Women's Health (NASDAQ:AWH) has announced significant board changes with the appointment of three new directors: Dr. Jeffrey Cohen, Cindy Hundorfean, and Jack Fraser. Dr. Cohen brings over 40 years of urological expertise and robot-assisted surgery experience, while Hundorfean contributes senior healthcare leadership experience as a partner at The CEO Advisory Network. Fraser adds financial expertise from his 25-year tenure at Seamark Capital.
The company also executed a $2.0 million equity purchase agreement with Triton Funds LP. The proceeds will support ongoing commercial activities, working capital, and general corporate purposes. A key focus remains on driving sales growth and completing their current endometriosis clinical study for the ENDOInform™ blood test.
Dr. Celeste Fralick will be departing the board after serving since February 2022. The board changes align with the upcoming annual shareholders meeting.
Aspira Women's Health (NASDAQ:AWH) has successfully achieved the second milestone of its $10 million ARPA-H Sprint for Women's Health award, receiving a $1.5 million payment. The milestone focused on scaling up R&D capabilities for developing ENDOinform™, a non-invasive blood test for endometriosis detection.
The project involves developing an AI-enabled algorithm combining protein and microRNA biomarkers with patient data. The second milestone included plans for building a new molecular laboratory, securing patents and licenses, and conducting market research for test positioning.
The company expects to complete the third milestone in Q2 2025, which will trigger another $1.5 million payment upon delivery of a biomarker algorithm technical report and voice of customer study framework. The program will continue through early 2026, providing non-dilutive funding for Aspira's growth.
Aspira Women's Health (AWH) reported its Q4 and full-year 2024 financial results, achieving record OvaSuite revenue of $9.2 million and 24,305 units sold. Q4 2024 highlights include:
- Product revenue up 9.5% to $2.3M
- OvaSuite tests increased 6.1% to 6,004 units
- Average unit price rose 4.3% to $391
- Gross profit margin improved to 63.4%
- Operating expenses decreased 8% to $4.9M
Full-year 2024 performance showed flat product revenue at $9.2M, with test volume up 1.3% and average unit price down 1% to $378. The company raised $5.75M through convertible notes ($1.36M) and ATM facility ($4.39M). Cash balance stands at $3.7M, with an additional $1.5M ARPA-H milestone payment pending.
Aspira Women's Health (NASDAQ:AWH) has announced the closing of a $1.37 million private placement of Senior Secured Convertible Promissory Notes due March 6, 2030. The notes, sold to existing and new accredited investors, will accrue interest at 3.34% payable quarterly.
The Convertible Notes can be converted into units comprising one share of common stock and 2.25 warrants at $0.25 per unit. The warrants are exercisable for five years at $0.50 per share, with an option to exercise at $0.25 per share between months 6-24 after issuance. The company maintains the right to convert the notes if total gross proceeds from sales reach $4 million.
The proceeds will support Aspira's ongoing commercial activities, general corporate purposes, and working capital. The securities sold in this private placement are not registered under the Securities Act of 1933.
Aspira Women's Health (NASDAQ:AWH) has announced the withdrawal of its Form S-1 Registration Statement (No. 333-284182) with the Securities and Exchange Commission (SEC). The Registration Statement, initially filed on January 8, 2025, was intended for a public offering. The company confirmed that the Registration Statement was never declared effective by the SEC, and no securities were sold in connection with the proposed offering.
The company, which focuses on developing gynecologic disease diagnostic tools, has decided not to pursue the public offering at this time. This announcement does not constitute an offer to sell or solicitation to buy the company's common stock or other securities.
Aspira Women's Health (NASDAQ:AWH) has announced the appointment of Ellen Beausang to its Board of Directors, effective February 10, 2025. Beausang, who currently serves as Chief Commercial Officer at BioReference Health, brings extensive experience in commercial strategy development within the diagnostics sector. The appointment comes at what the company describes as a commercial inflection point, as it focuses on growing existing business lines and developing new diagnostic tests to expand market opportunities.
Beausang's background includes over 5 years at BioReference Health and previous executive positions at major healthcare companies including Pfizer, Thermo Fisher Diagnostics, and Quest Diagnostics. CEO Michael Buhle highlighted her expertise as valuable for accelerating business growth and advancing the company's mission in women's healthcare.
Aspira Women's Health (AWH) has announced key leadership changes. Mike Buhle has been appointed as SVP of Commercial Operations, bringing over 25 years of experience in driving commercial growth and new product launches in diagnostics and life science tools. Buhle previously served as Chief Commercial Officer at Biovision Diagnostics and VP of Sales, Americas for Congenica.
Additionally, Interim CFO John Kallassy will depart on January 10, 2025. The company has retained James O'Brien as CFO advisor, who brings 30+ years of experience in biotechnology, pharmaceutical, and medical device industries. O'Brien, founder of Great Island Advisors , previously served as CFO of Faron Pharmaceuticals and Cognition Therapeutics.
Both Buhle and O'Brien will join interim CEO Dr. Sandra Milligan for meetings during the JP Morgan Healthcare Conference week starting January 13th in San Francisco.
Aspira Women's Health (NASDAQ: AWH) announced that CEO Nicole Sandford will step down immediately for personal reasons, with Dr. Sandra Milligan, the company's President, appointed as interim CEO. During Sandford's tenure, the company launched the OvaWatch multivariate assay for ovarian cancer detection and received a $10 million award from the Advanced Research Projects Agency for Health to complete their endometriosis detection product. Sandford will remain as a consultant to ensure a smooth transition while the company conducts a nationwide search for a permanent CEO. The Board praised Sandford's contributions in stabilizing the business and building a strong team for future growth.
